Deep Track Capital
Latest statistics and disclosures from Deep Track Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are XBI, GH, IMVT, TARS, PCVX, and represent 38.77% of Deep Track Capital's stock portfolio.
- Added to shares of these 10 stocks: ALMS (+$149M), NUVL (+$141M), OCUL (+$98M), GMAB (+$98M), DFTX (+$57M), ALKS (+$56M), VERA (+$52M), GH (+$50M), CNTA (+$46M), ATAI (+$43M).
- Started 16 new stock positions in PSNL, SLDB, LRMR, ATAI, APGE, ALMS, Veradermics, KURA, NUVL, PMN. DFTX, ACRS, BEAM, IPSC, GMAB, CRVS.
- Reduced shares in these 10 stocks: DVAX (-$242M), APLS (-$129M), CYTK (-$129M), BMRN (-$65M), MAZE (-$23M), MNMD (-$22M), VRDN (-$22M), CLDX (-$20M), Atai Life Sciences Nv (-$19M), XENE (-$16M).
- Sold out of its positions in ANL, DVAX, MNMD, MNPR, RAPT, XENE, BHVN, Atai Life Sciences Nv.
- Deep Track Capital was a net buyer of stock by $580M.
- Deep Track Capital has $6.1B in assets under management (AUM), dropping by 9.18%.
- Central Index Key (CIK): 0001856083
Tip: Access up to 7 years of quarterly data
Positions held by Deep Track Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Deep Track Capital
Deep Track Capital holds 63 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Spdr Series Trust State Street Spd Put Option (XBI) | 20.9 | $1.3B | 10M | 127.73 |
|
|
| Guardant Health (GH) | 5.0 | $308M | +19% | 3.3M | 92.37 |
|
| Immunovant (IMVT) | 4.7 | $286M | 12M | 24.84 |
|
|
| Tarsus Pharmaceuticals (TARS) | 4.1 | $253M | +19% | 3.6M | 70.15 |
|
| Vaxcyte (PCVX) | 4.1 | $250M | +7% | 4.3M | 58.11 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 3.4 | $206M | +4% | 4.3M | 48.20 |
|
| Axsome Therapeutics (AXSM) | 3.0 | $186M | -4% | 1.1M | 169.02 |
|
| Apellis Pharmaceuticals (APLS) | 3.0 | $182M | -41% | 4.5M | 40.23 |
|
| Ocular Therapeutix (OCUL) | 2.7 | $167M | +143% | 20M | 8.47 |
|
| Vera Therapeutics Cl A (VERA) | 2.7 | $165M | +45% | 4.1M | 40.23 |
|
| Alumis (ALMS) | 2.4 | $149M | NEW | 6.8M | 22.03 |
|
| Ionis Pharmaceuticals (IONS) | 2.4 | $146M | +14% | 2.0M | 75.09 |
|
| Nuvalent Inc-a (NUVL) | 2.3 | $141M | NEW | 1.4M | 102.45 |
|
| Alkermes SHS (ALKS) | 2.1 | $127M | +79% | 3.6M | 35.36 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 2.0 | $125M | +57% | 3.2M | 39.72 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 2.0 | $120M | +39% | 6.4M | 18.64 |
|
| Maze Therapeatics (MAZE) | 1.7 | $104M | -18% | 3.5M | 29.85 |
|
| Oruka Therapeutics (ORKA) | 1.6 | $100M | -5% | 2.0M | 49.05 |
|
| Nurix Therapeutics (NRIX) | 1.6 | $98M | -9% | 6.3M | 15.50 |
|
| Genmab A/s Sponsored Ads (GMAB) | 1.6 | $98M | NEW | 3.7M | 26.83 |
|
| Cytokinetics Com New (CYTK) | 1.5 | $91M | -58% | 1.4M | 65.91 |
|
| Grail (GRAL) | 1.5 | $89M | +68% | 1.7M | 51.68 |
|
| Lb Pharmaceuticals Com Shs (LBRX) | 1.4 | $83M | 3.4M | 24.66 |
|
|
| Mbx Biosciences (MBX) | 1.3 | $82M | -15% | 2.8M | 29.85 |
|
| Bicara Therapeutics (BCAX) | 1.3 | $81M | +55% | 4.1M | 19.89 |
|
| Compass Pathways Sponsored Ads (CMPS) | 1.1 | $67M | +65% | 12M | 5.53 |
|
| BioMarin Pharmaceutical (BMRN) | 1.1 | $65M | -50% | 1.2M | 56.49 |
|
| Bridgebio Pharma (BBIO) | 1.0 | $63M | +3% | 841k | 74.26 |
|
| Immunocore Hldgs Ads (IMCR) | 1.0 | $58M | -3% | 1.9M | 30.15 |
|
| Tango Therapeutics (TNGX) | 0.9 | $58M | +12% | 2.8M | 20.92 |
|
| Definium Therapeutics Com Shs (DFTX) | 0.9 | $57M | NEW | 3.0M | 18.90 |
|
| Terns Pharmaceuticals (TERN) | 0.9 | $57M | +39% | 1.1M | 52.72 |
|
| Geron Corporation (GERN) | 0.8 | $47M | -2% | 32M | 1.49 |
|
| Biosante Pharmaceuticals (ANIP) | 0.8 | $46M | +25% | 600k | 76.90 |
|
| Cormedix Inc cormedix (CRMD) | 0.7 | $43M | +18% | 6.3M | 6.79 |
|
| Ataibeckley Com Shs (ATAI) | 0.7 | $43M | NEW | 12M | 3.54 |
|
| Celldex Therapeutics Com New (CLDX) | 0.7 | $41M | -32% | 1.3M | 31.72 |
|
| Cogent Biosciences (COGT) | 0.6 | $39M | +120% | 1.0M | 38.49 |
|
| Corvus Pharmaceuticals (CRVS) | 0.6 | $37M | NEW | 2.5M | 14.63 |
|
| Dyne Therapeutics (DYN) | 0.6 | $36M | -24% | 2.0M | 18.13 |
|
| Soleno Therapeutics (SLNO) | 0.6 | $36M | +7% | 1.1M | 33.48 |
|
| Aclaris Therapeutics (ACRS) | 0.6 | $35M | NEW | 9.3M | 3.75 |
|
| Veradermics Common Stock | 0.5 | $32M | NEW | 500k | 63.15 |
|
| Verastem Com New (VSTM) | 0.5 | $30M | 5.7M | 5.30 |
|
|
| Engene Holdings (ENGN) | 0.5 | $30M | 4.4M | 6.81 |
|
|
| Miragen Therapeutics (VRDN) | 0.4 | $27M | -44% | 1.4M | 19.56 |
|
| X4 Pharmaceuticals Com New (XFOR) | 0.4 | $26M | +26% | 6.3M | 4.13 |
|
| Solid Biosciences Com New (SLDB) | 0.4 | $26M | NEW | 3.6M | 7.20 |
|
| Enanta Pharmaceuticals (ENTA) | 0.4 | $25M | 2.0M | 12.63 |
|
|
| Apogee Therapeutics (APGE) | 0.4 | $24M | NEW | 285k | 84.17 |
|
| Kura Oncology (KURA) | 0.4 | $22M | NEW | 2.6M | 8.13 |
|
| Century Therapeutics (IPSC) | 0.4 | $21M | NEW | 9.5M | 2.26 |
|
| Beam Therapeutics (BEAM) | 0.3 | $20M | NEW | 821k | 23.83 |
|
| Context Therapeutics (CNTX) | 0.3 | $19M | 7.4M | 2.62 |
|
|
| Personalis Ord (PSNL) | 0.3 | $19M | NEW | 3.0M | 6.37 |
|
| Janux Therapeutics (JANX) | 0.3 | $17M | +1225% | 1.2M | 13.90 |
|
| Promis Neurosciences Com Shs (PMN) | 0.2 | $11M | NEW | 836k | 12.70 |
|
| Crescent Biopharma (CBIO) | 0.1 | $8.3M | 454k | 18.37 |
|
|
| Inventiva Sa Ads (IVA) | 0.1 | $6.8M | +149% | 1.2M | 5.55 |
|
| Larimar Therapeutics (LRMR) | 0.1 | $6.8M | NEW | 1.5M | 4.50 |
|
| Cybin Com New (HELP) | 0.1 | $6.3M | -29% | 1.3M | 4.80 |
|
| Billiontoone Cl A (BLLN) | 0.1 | $3.9M | 50k | 78.94 |
|
|
| Aligos Therapeutics Com New (ALGS) | 0.1 | $3.3M | 444k | 7.43 |
|
Past Filings by Deep Track Capital
SEC 13F filings are viewable for Deep Track Capital going back to 2021
- Deep Track Capital 2026 Q1 filed May 15, 2026
- Deep Track Capital 2025 Q4 filed Feb. 13, 2026
- Deep Track Capital 2025 Q3 filed Nov. 14, 2025
- Deep Track Capital 2025 Q2 filed Aug. 14, 2025
- Deep Track Capital 2025 Q1 filed May 15, 2025
- Deep Track Capital 2024 Q4 filed Feb. 14, 2025
- Deep Track Capital 2024 Q3 filed Nov. 14, 2024
- Deep Track Capital 2024 Q2 filed Aug. 14, 2024
- Deep Track Capital 2024 Q1 filed May 15, 2024
- Deep Track Capital 2023 Q4 filed Feb. 14, 2024
- Deep Track Capital 2023 Q3 filed Nov. 14, 2023
- Deep Track Capital 2023 Q2 restated filed Sept. 6, 2023
- Deep Track Capital 2023 Q2 filed Aug. 14, 2023
- Deep Track Capital 2023 Q1 filed May 15, 2023
- Deep Track Capital 2022 Q4 filed Feb. 14, 2023
- Deep Track Capital 2022 Q3 filed Nov. 14, 2022